ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Bromodomain-containing protein 4 (BRD4) is overexpressed in thyroid carcinoma, making it a significant therapeutic target.
• Cereblon-based Proteolysis Targeting Chimeras (PROTACs) offer a novel approach for targeted protein degradation.

Purpose of the Study:

• To investigate the efficacy of ARV-825, a novel BRD4-targeting PROTAC, in human thyroid carcinoma cells.
• To evaluate the therapeutic potential of ARV-825 in preclinical models of thyroid cancer.

Main Methods:

• ARV-825 treatment of TPC-1 and primary human thyroid carcinoma cells.
• Assessment of cell viability, proliferation, migration, and apoptosis.
• Analysis of BRD4 protein degradation and downstream target modulation (c-Myc, Bcl-xL, cyclin D1).
• In vivo studies using TPC-1 xenograft models in immunodeficient mice.

Main Results:

• ARV-825 demonstrated potent inhibition of thyroid carcinoma cell viability, proliferation, and migration.
• ARV-825 induced significant apoptosis and degradation of BRD4 protein and its targets.
• Compared to small molecule inhibitors, ARV-825 showed superior potency.
• Oral administration of ARV-825 suppressed tumor growth in preclinical xenograft models.

Conclusions:

• ARV-825 effectively induces BRD4 protein degradation, leading to the inhibition of thyroid carcinoma cell growth both in vitro and in vivo.
• ARV-825 represents a promising therapeutic strategy for thyroid carcinoma targeting BRD4.